Scale Up of Therapeutic Viral Vectors for Gene Therapy with PALL

28 October 2021
Scaling up therapeutic viral vectors for gene therapy to meet clinical trial and market needs.

“When we think about cell and gene therapy scaling and industrialisation, one question that needs to be answered is what scale is needed to match the therapy demand?”

For this technology demonstration, Emmanuelle Cameau, Viral Vector & Gene Therapy Technical Manager at PALL Corporation, outlines how to match manufacturing scale to therapy demand, providing example calculations for defining your manufacturing platform and scale before discussing the overall concept of scaling up therapeutic viral vectors for gene therapy in the context of PALL’s services, through case studies.

Phacilitate member? Watch this video and join the conversation via the network.

Not yet a member?
Join Today.